NewAmsterdam Pharma (NAMS) to Release Quarterly Earnings on Wednesday

NewAmsterdam Pharma (NASDAQ:NAMS) is expected to be releasing its earnings data before the market opens on Wednesday, February 26th. Analysts expect NewAmsterdam Pharma to post earnings of ($0.48) per share for the quarter.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ:NAMS opened at $18.57 on Monday. NewAmsterdam Pharma has a 1-year low of $15.19 and a 1-year high of $27.29. The business’s 50 day moving average is $23.17 and its 200-day moving average is $20.24.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on NAMS shares. HC Wainwright reissued a “buy” rating and issued a $48.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Royal Bank of Canada restated an “outperform” rating and issued a $40.00 price objective on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Scotiabank raised their target price on NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a “sector outperform” rating in a report on Wednesday, December 11th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $36.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, December 5th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, NewAmsterdam Pharma currently has an average rating of “Buy” and an average target price of $41.60.

Insider Activity at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, major shareholder Nap B.V. Forgrowth sold 29,846 shares of the stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $25.54, for a total value of $762,266.84. Following the completion of the transaction, the insider now directly owns 10,656,172 shares in the company, valued at approximately $272,158,632.88. This trade represents a 0.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 404,927 shares of company stock valued at $10,390,787 over the last quarter. 19.50% of the stock is owned by corporate insiders.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.